Omeros' proprietary GPCR program delivers new target and approach in cancer immunotherapy
Omeros announced that its small-molecule inhibitors against GPR174, an orphan G protein-coupled receptor narrowly expressed in immune cells and linked to cancers, substantially and statistically significantly boost levels of cytokines and reduce the population regulatory T cells. December 05, 2016